Precision Genetics and Personalized GLP-1 Response Not all men respond identically to GLP-1 medications due to genetic variation in peptide signaling pathways
Early studies on GLP-1s show that people often lose a significant percentage of lean mass as part of their total weight loss sometimes 2040% of whats lost isnt fat, but muscle and water
The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes
Semaglutide may be the better option if: Cost is the primary concern compounded semaglutide offers the most affordable path to GLP-1 therapy in 2026 You have cardiovascular disease the SELECT trial demonstrated significant reduction in major cardiovascular events with semaglutide, giving it the strongest CV evidence base of any GLP-1 medication
The WHO (2021, 6th edition) defines the lower reference limit for normal total motility as 42%, with progressive motility at 30%, 19 and L-carnitine helps maintain sperm within this healthy range, which is particularly important for men with asthenospermia
